Gain Therapeutics Inc., a clinical-stage biotechnology company, has announced its intention to conduct a public offering of its common stock and warrants to purchase common stock. The company plans to use the net proceeds from this offering to further the clinical and nonclinical development of its lead product candidate, GT-02287, which targets neurodegenerative diseases such as GBA1 Parkinson's disease. Newbridge Securities Corporation is serving as the sole book-running manager for this proposed offering. The offering will be made through a prospectus, and the final terms will depend on the prevailing market conditions at the time of pricing.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。